BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10542 related articles for article (PubMed ID: 15122079)

  • 1. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
    Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
    Invest New Drugs; 2004 Aug; 22(3):315-22. PubMed ID: 15122079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
    J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
    Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
    Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
    Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
    J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
    Schwartz GK; Ilson D; Saltz L; O'Reilly E; Tong W; Maslak P; Werner J; Perkins P; Stoltz M; Kelsen D
    J Clin Oncol; 2001 Apr; 19(7):1985-92. PubMed ID: 11283131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
    Stadler WM; Vogelzang NJ; Amato R; Sosman J; Taber D; Liebowitz D; Vokes EE
    J Clin Oncol; 2000 Jan; 18(2):371-5. PubMed ID: 10637252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Kouroukis CT; Belch A; Crump M; Eisenhauer E; Gascoyne RD; Meyer R; Lohmann R; Lopez P; Powers J; Turner R; Connors JM;
    J Clin Oncol; 2003 May; 21(9):1740-5. PubMed ID: 12735303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
    Zhai S; Senderowicz AM; Sausville EA; Figg WD
    Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
    Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of perifosine in previously untreated patients with metastatic melanoma.
    Ernst DS; Eisenhauer E; Wainman N; Davis M; Lohmann R; Baetz T; Belanger K; Smylie M
    Invest New Drugs; 2005 Dec; 23(6):569-75. PubMed ID: 16034524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of flavopiridol in patients with advanced colorectal cancer.
    Aklilu M; Kindler HL; Donehower RC; Mani S; Vokes EE
    Ann Oncol; 2003 Aug; 14(8):1270-3. PubMed ID: 12881391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
    Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
    Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
    Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
    Innocenti F; Stadler WM; Iyer L; Ramírez J; Vokes EE; Ratain MJ
    Clin Cancer Res; 2000 Sep; 6(9):3400-5. PubMed ID: 10999721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
    Liu G; Gandara DR; Lara PN; Raghavan D; Doroshow JH; Twardowski P; Kantoff P; Oh W; Kim K; Wilding G
    Clin Cancer Res; 2004 Feb; 10(3):924-8. PubMed ID: 14871968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
    Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.
    Morris DG; Bramwell VH; Turcotte R; Figueredo AT; Blackstein ME; Verma S; Matthews S; Eisenhauer EA
    Sarcoma; 2006; 2006():64374. PubMed ID: 17251659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 528.